Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 0.92 |
| ▸ | ABL1 | P00519 | 7/20 | 0.92 |
| ▸ | BCR | P11274 | 4/20 | 0.92 |
| ▸ | ABL2 | P42684 | 4/20 | 0.92 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.92 |
| ▸ | STK25 | O00506 | 1/20 | 0.92 |
| ▸ | CIT | O14578 | 1/20 | 0.92 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.92 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.92 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.92 |
| ▸ | CASK | O14936 | 1/20 | 0.92 |
| ▸ | GAK | O14976 | 1/20 | 0.92 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.92 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.92 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.92 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.92 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.92 |
| ▸ | JAK2 | O60674 | 1/20 | 0.92 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.92 |
| ▸ | ULK1 | O75385 | 1/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30453317 | 1.00 | SRC (0.92) | SRCABL1BCRABL2KCNH2 | |
| SCHEMBL30453202 | 0.96 | SRC (0.85) | SRCABL1BCRABL2KCNH2 | |
| SCHEMBL676654 | 0.96 | SRC (0.85) | SRCABL1BCRABL2KCNH2 | |
| Bosutinib SCHEMBL29350234 | 0.96 | SRC (1.00) | SRCABL1BCRABL2KCNH2 | |
| Bosutinib SCHEMBL29428159 | 0.96 | SRC (1.00) | SRCABL1BCRABL2KCNH2 | |
| Bosutinib SCHEMBL2887945 | 0.96 | SRC (1.00) | SRCABL1BCRABL2KCNH2 | |
| Bosutinib SCHEMBL19207253 | 0.96 | SRC (1.00) | SRCABL1BCRABL2KCNH2 | |
| Bosutinib SCHEMBL158390 | 0.96 | SRC (1.00) | SRCABL1BCRABL2KCNH2 | |
| Bosutinib SCHEMBL29389315 | 0.96 | SRC (1.00) | SRCABL1BCRABL2KCNH2 | |
| SCHEMBL5251926 | 0.94 | SRC (1.00) | SRCABL1BCRABL2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3002009-A2 | TREATMENT OF IMATINIB RESISTANT LEUKEMIA USING 4-AMINOQUINOLINE-3-CARBONITRILES | Wyeth LLC (US) | 2016-04-06 | — | — | EP | claimed |
| EP-2777704-A2 | Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles | Wyeth LLC (US) | 2014-09-17 | — | — | EP | claimed |
| EP-2478905-A2 | Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles | Wyeth LLC (US) | 2012-07-25 | — | — | EP | claimed |
| EP-2152267-A2 | TREATMENT OF IMATINIB RESISTANT LEUKEMIA USING 4-AMINOQUINOLINE-3-CARBONITRILES | Wyeth LLC (US) | 2010-02-17 | — | — | EP | claimed |
| US-20100029677-A1 | 4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) | WYETH (US) | 2010-02-04 | — | — | US | claimed |
| US-20080318971-A1 | using bosutinib | WYETH (US) | 2008-12-25 | — | — | US | claimed |
| US-7468379-B2 | Inhibition of osteolytic lesions by SRC kinase inhibitors | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-12-23 | — | — | US | claimed |
| WO-2008150957-A2 | TREATMENT OF IMATINIB RESISTANT LEUKEMIA USING 4-AMINOQUINOLINE-3-CARBONITRILES | WYETH (US) | 2008-12-11 | — | — | WO | claimed |
| US-7417148-B2 | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) | WYETH (US) | 2008-08-26 | — | — | US | claimed |
| EP-1896020-A1 | INHIBITION OF OSTEOLYTIC LESIONS BY SRC KINASE INHIBITORS | The Board of Regents of The University of Texas System (US) | 2008-03-12 | — | — | EP | claimed |
| US-20070004748-A1 | Inhibition of osteolytic lesions by SRC kinase inhibitors | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2007-01-04 | — | — | US | claimed |
| WO-2006138590-A1 | INHIBITION OF OSTEOLYTIC LESIONS BY SRC KINASE INHIBITORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-12-28 | — | — | WO | claimed |
| EP-1680119-A1 | 4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) | Wyeth (US) | 2006-07-19 | — | — | EP | claimed |
| EP-1594502-A1 | 4- (2,4-DICHLORO-5-METHOXYPHENYL)AMINO -6-ALKOXY-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF ISCHEMIC INJURY | Wyeth (US) | 2005-11-16 | — | — | EP | claimed |
| WO-2005047259-A1 | 4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) | WYETH (US) | 2005-05-26 | — | — | WO | claimed |
| WO-2005046693-A1 | 4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) | WYETH (US) | 2005-05-26 | — | — | WO | claimed |
| US-20050101780-A1 | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) | WYETH (US) | 2005-05-12 | — | — | US | claimed |
| US-20040229880-A1 | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury | WYETH | 2004-11-18 | — | — | US | claimed |
| WO-2004075898-A1 | 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-ALKOXY-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF ISCHEMIC INJURY | WYETH (US) | 2004-09-10 | — | — | WO | claimed |
| EP-4599890-A2 | SUNITINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2025-08-13 | — | — | EP | disclosed |
| US-20240318144-A1 | MEDIA FOR CULTURING NAIVE HUMAN PLURIPOTENT STEM CELLS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-09-26 | — | — | US | disclosed |
| US-11920164-B2 | Media for culturing naive human pluripotent stem cells | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-03-05 | — | — | US | disclosed |
| EP-3194572-B1 | MEDIA FOR CULTURING PLURIPOTENT STEM CELLS | YEDA RES & DEV (IL) | 2023-10-25 | — | — | EP | disclosed |
| CN-113181362-B | Medicament for preventing and/or treating amyotrophic lateral sclerosis | 国立大学法人京都大学 | 2023-06-13 | — | — | CN | disclosed |
| US-20210363495-A1 | CULTURE MEDIA FOR PLURIPOTENT STEM CELLS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2021-11-25 | — | — | US | disclosed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| CN-113181362-A | Agent for preventing and/or treating amyotrophic lateral sclerosis | 国立大学法人京都大学 | 2021-07-30 | — | — | CN | disclosed |
| EP-3002009-B1 | TREATMENT OF IMATINIB RESISTANT CHRONIC MYELOGENOUS LEUKEMIA HAVING THE MUTATON 1457T>C IN THE BCRABL GENE USING THE COMPOUND BOSUTINIB | WYETH LLC (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3789027-A1 | BOSUTINIB, SUNITINIB, TIVOZANIB, IMATINIB, NILOTINIB, REBASTINIB OR BAFETINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2021-03-10 | — | — | EP | disclosed |
| EP-2872161-B1 | DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS | DEL MAR PHARMACEUTICALS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-20200113968-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR DOWNREGULATION OF PRO-INFLAMMATORY CYTOKINES | BAUSCH HEALTH IRELAND LTD (IE) | 2020-04-16 | — | — | US | disclosed |
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2018-01-04 | — | — | US | disclosed |
| EP-3246046-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-20170275593-A1 | MEDIA FOR CULTURING PLURIPOTENT STEM CELLS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-09-28 | — | — | US | disclosed |
| EP-3194572-A1 | MEDIA FOR CULTURING PLURIPOTENT STEM CELLS | Yeda Research and Development Co. Ltd. (IL) | 2017-07-26 | — | — | EP | disclosed |
| EP-3065757-A2 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR DOWNREGULATION OF PRO-INFLAMMATORY CYTOKINES | Synergy Pharmaceuticals Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20160235807-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR DOWNREGULATION OF PRO-INFLAMMATORY CYTOKINES | SYNERGY PHARMACEUTICALS INC. | 2016-08-18 | — | — | US | disclosed |
| EP-3002009-A2 | TREATMENT OF IMATINIB RESISTANT LEUKEMIA USING 4-AMINOQUINOLINE-3-CARBONITRILES | Wyeth LLC (US) | 2016-04-06 | — | — | EP | disclosed |
| WO-2016016894-A1 | MEDIA FOR CULTURING PLURIPOTENT STEM CELLS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-02-04 | — | — | WO | disclosed |
| US-9101631-B2 | Combination therapy based on SRC and aurora kinase inhibition for the treatment of cancer | GEORGETOWN UNIVERSITY (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2015-07-02 | — | — | US | disclosed |
| EP-2872161-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | Del Mar Pharmaceuticals (CA) | 2015-05-20 | — | — | EP | disclosed |
| EP-2777704-A2 | Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles | Wyeth LLC (US) | 2014-09-17 | — | — | EP | disclosed |
| EP-1896020-B1 | SKI 606 as src kinase inhibitor for treating osteolytic lesions | UNIV TEXAS (US) | 2014-08-20 | — | — | EP | disclosed |
| EP-2478905-B1 | Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles | WYETH LLC (US) | 2014-05-14 | — | — | EP | disclosed |
| WO-2014004376-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (CA) | 2014-01-03 | — | — | WO | disclosed |
| EP-2478905-A2 | Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles | Wyeth LLC (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20110281935-A1 | Combination Therapy Based on SRC and Aurora Kinase Inhibition for the Treatment of Cancer | THE INSTITUTE FOR CANCER RESEARCH | 2011-11-17 | — | — | US | disclosed |
| US-7919625-B2 | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) | WYETH LLC (US) | 2011-04-05 | — | — | US | disclosed |
| WO-2010068951-A1 | COMBINATION THERAPY BASED ON SRC AND AURORA KINASE INHIBITION FOR THE TREATMENT OF CANCER | FOX CHASE CANCER CENTER (US) | 2010-06-17 | — | — | WO | disclosed |
| EP-2152267-A2 | TREATMENT OF IMATINIB RESISTANT LEUKEMIA USING 4-AMINOQUINOLINE-3-CARBONITRILES | Wyeth LLC (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20100029677-A1 | 4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| US-20080318971-A1 | using bosutinib | WYETH (US) | 2008-12-25 | — | — | US | disclosed |
| US-7468379-B2 | Inhibition of osteolytic lesions by SRC kinase inhibitors | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-12-23 | — | — | US | disclosed |
| WO-2008150957-A2 | TREATMENT OF IMATINIB RESISTANT LEUKEMIA USING 4-AMINOQUINOLINE-3-CARBONITRILES | WYETH (US) | 2008-12-11 | — | — | WO | disclosed |
| US-7417148-B2 | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) | WYETH (US) | 2008-08-26 | — | — | US | disclosed |
| EP-1896020-A1 | INHIBITION OF OSTEOLYTIC LESIONS BY SRC KINASE INHIBITORS | The Board of Regents of The University of Texas System (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20070004748-A1 | Inhibition of osteolytic lesions by SRC kinase inhibitors | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2007-01-04 | — | — | US | disclosed |
| WO-2006138590-A1 | INHIBITION OF OSTEOLYTIC LESIONS BY SRC KINASE INHIBITORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-12-28 | — | — | WO | disclosed |
| EP-1680119-A1 | 4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) | Wyeth (US) | 2006-07-19 | — | — | EP | disclosed |
| EP-1594502-A1 | 4- (2,4-DICHLORO-5-METHOXYPHENYL)AMINO -6-ALKOXY-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF ISCHEMIC INJURY | Wyeth (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2005047259-A1 | 4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) | WYETH (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005046693-A1 | 4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) | WYETH (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050101780-A1 | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) | WYETH (US) | 2005-05-12 | — | — | US | disclosed |
| US-20040229880-A1 | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury | WYETH | 2004-11-18 | — | — | US | disclosed |
| WO-2004075898-A1 | 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-ALKOXY-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF ISCHEMIC INJURY | WYETH (US) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004075898-A1 | 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-ALKOXY-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF ISCHEMIC INJURY | WYETH (US) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | WHR1, AIPL1, TDP1 | SRC 1484/4885ABL1 698/4885BCR 64/4885 |
| US-20200113968-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR DOWNREGULATION OF PRO-INFLAMMATORY CYTOKINES | GUCY1A1, GUCY1A2, GUCY1B2 | SRC 1570/4885ABL1 3557/4885BCR 3131/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | SRC 1586/4885ABL1 746/4885BCR 48/4885 |
| US-20070004748-A1 | Inhibition of osteolytic lesions by SRC kinase inhibitors | SRC, CAMK1, SOST | SRC 1/4885ABL1 1351/4885BCR 558/4885 |
| US-20040229880-A1 | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury | TNNI3, TXN2, AIFM1 | SRC 4373/4885ABL1 655/4885BCR 3690/4885 |
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | WEE2, WEE1, ERBB2 | SRC 276/4885ABL1 214/4885BCR 1923/4885 |
| US-20160235807-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR DOWNREGULATION OF PRO-INFLAMMATORY CYTOKINES | GUCY1A1, GUCY1A2, GUCY1B2 | SRC 1570/4885ABL1 3557/4885BCR 3131/4885 |
| US-20050101780-A1 | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) | ABL1, MCL1, NPM1 | SRC 244/4885ABL1 1/4885BCR 4/4885 |
| US-20080318971-A1 | using bosutinib | ABL1, BCR, MCL1 | SRC 345/4885ABL1 1/4885BCR 2/4885 |
| US-20100029677-A1 | 4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) | ABL1, MCL1, NPM1 | SRC 244/4885ABL1 1/4885BCR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.